The overexpression of CEA occurs in >90% of colorectal cancers (CRC) and 60% of other types of cancer, including gastric, lung, and pancreatic cancers [27]; thus, it has been widely used as a serum tumor marker. This evidence concerns the gene CEACAM5 and colorectal carcinoma.